Cogstate’s Post

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and UCL, gives you his update in this MEDtalk. #Alzheimers 

2023 was a big year for us to celebrate as we accomplished multiple firsts in the global fight against Alzheimer’s disease. Among these milestones, our Precivity™-related biomarkers appeared in multiple global phase 3 clinical efficacy studies to help demonstrate biological activity of anti-amyloid therapies. In August, we launched the PrecivityAD2™ blood test in the U.S., a unique innovation with high concordance to Amyloid PET and CSF that’s helping to transform clinical care for individuals with cognitive impairment. Then, on World Alzheimer’s Day, we expanded its reach to #Brazil. A partnership with Grupo Fleury is helping Brazilians receive accurate and early Alzheimer’s disease diagnoses.   https://lnkd.in/ekPAmH5g   #yearinreview #Brazil #diagnosis #alzheimersdisease

September is World #Alzheimers Month There have been significant advances in Alzheimer's research - bringing hope to this highly prevalent disease. In the last few years alone, we've witnessed the approval of the first disease-modifying treatments, learned about new pathological factors affecting disease development and will soon have access to blood-based biomarker tests. This is only the start of changing the course and impact of this devastating disease. Learn more: https://lnkd.in/gHZt7_vv $INM #Awareness #Research #AlzheimersFuture

MR biomarkers are mapping the progression of the Duchenne and Becker muscular dystrophy. # Duchenne muscular dystrophy and #Becker muscular dystrophy

Identifying Alzheimer’s disease (AD) during the pre-clinical stage remains a challenge, but we’re finding hope in precision medicine to slow or even prevent the disease up to 20 years before symptoms appear. Watch to learn how #MyCompany is using digital, blood, and imaging biomarkers to help us identify the disease in its earliest stages and improve patient outcomes for those living with AD.   If you’re curious about biomarkers in early intervention of disease, I encourage you to read my blog post – and let me know what you think about the future of AD research in the comments: https://bit.ly/44DiXNu     #ENDALZ #AlzheimersDisease #MyCompany #AlzheimersDiseaseMonth 

MR biomarkers predict clinical function in boys with #Duchenne muscular dystrophy. Read more about our experience predicting disease progression and treatment efficacy for DMD: https://lnkd.in/eR74aw8Q

Alzheimer's disease diagnosis is on the brink of transformation with blood-based biomarker (BBM) tests. 🧠 🩸 Simpler, cheaper, and less invasive than current methods, blood biomarkers—detectable through a simple blood sample—are proving to be as sensitive as existing diagnostic tools, with accuracies above 90%. BBMs can be deployed in primary care, enhancing early diagnosis and reducing health disparities.  Lucent Diagnostics, part of Quanterix, is leading this revolution, partnering with global initiatives to implement BBMs in diverse settings. These advancements pave the way for accessible, easily administered tests, enabling early detection and better treatment outcomes. Read more ➡️

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and University College London, gives you his update in this MEDtalk. #Alzheimers 

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and University College London, gives you his update in this MEDtalk. #Alzheimers 

Most viewed in the last 7 days from JAMA: Study prospectively evaluates a clinically available Alzheimer disease blood test in primary care and secondary care using predefined biomarker cutoff values. https://ja.ma/4d7eebB